(NASDAQ: TVTX) Travere Therapeutics's forecast annual revenue growth rate of 32.4% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 90.96%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.86%.
Travere Therapeutics's revenue in 2025 is $333,866,000.On average, 6 Wall Street analysts forecast TVTX's revenue for 2025 to be $36,892,090,011, with the lowest TVTX revenue forecast at $35,402,315,369, and the highest TVTX revenue forecast at $40,870,081,571. On average, 6 Wall Street analysts forecast TVTX's revenue for 2026 to be $49,488,454,170, with the lowest TVTX revenue forecast at $41,790,884,063, and the highest TVTX revenue forecast at $55,132,269,251.
In 2027, TVTX is forecast to generate $70,758,100,350 in revenue, with the lowest revenue forecast at $60,051,832,613 and the highest revenue forecast at $80,617,015,861.